Clarametyx Biosciences is targeting a universal structure within biofilms in order to eliminate bacterial defenses and drastically increase their vulnerability to immune or antibiotic intervention. Founded n 2020, Clarametyx is focused on addressing the challenge of biofilm-associated infections. These infections are often resistant to immune response or standard antibiotic regimens due to an extracellular matrix […]

View post to subscribe to site newsletter.

Founded in 2020, Myricx Pharma is developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer. The company is also exploring potential applications across other diseases. Based on research from Imperial College London and the Francis Crick Institute, Myricx says it has uncovered one of the most promising new areas of biology; […]

View post to subscribe to site newsletter.

Founded in 2020 as a spin-off from VBI in Belgium, Animab builds on a proprietary platform technology that enables efficient generation of monoclonal antibodies to prevent intestinal infections in farm animals. This new class of orally administered antibodies is designed to improve the health and performance of animals by targeting specific disease-causing pathogens. The company […]

View post to subscribe to site newsletter.